Skip to main content
SpringerLink
Log in

Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Clozapine, an atypical antipsychotic, is effective in the treatment of schizophrenia. However, its association with serious haematological toxicity has restricted its use to the management of patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agent, for which it remains the antipsychotic agent of choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kerwin R. When should clozapine be initiated in schizophrenia? Some arguments for and against earlier use of clozapine. CNS Drugs. 2007;21(4):267–78.

    Article  PubMed  CAS  Google Scholar 

  2. Wagstaff AJ, Bryson HM. Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs. 1995;4(5):370–400.

    Article  CAS  Google Scholar 

  3. Fakra E, Azorin JM. Clozapine for the treatment of schizophrenia. Expert Opin Pharmacother. 2012;13(13):1923–35.

    Article  PubMed  CAS  Google Scholar 

  4. Englisch S, Zink M. Treatment-resistant schizophrenia: evidence-based strategies. Mens Sana Monogr. 2012;10:20–32.

    Article  PubMed  Google Scholar 

  5. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6(3):134–44.

    Article  PubMed  Google Scholar 

  6. Raja M. Clozapine safety, 35 years later. Curr Drug Saf. 2011;6(3):164–84.

    Article  PubMed  CAS  Google Scholar 

  7. Hill M, Feudenreich O. Clozapine: key discussion points for prescribiers. Clin Schizophr Relat Psychoses. 2013;6(4):177–85.

    Article  PubMed  Google Scholar 

  8. Mcilwain ME, Harrison J, Wheeler AJ, et al. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric Dis Treat. 2011;7:135–49.

    CAS  Google Scholar 

  9. Pinazan (clozapine 25 mg and 100 mg tablets): summary of product characteristics [in Portuguese]. Itapira, Brazil: Cristália Laboratories Limited, 2012.

  10. Clozaril 25 mg and 100 mg tablets: summary of product characteristics. Camberley: Novartis Pharmaceuticals UK Limited; 2012.

  11. Meltzer HY, Bastani B, Young-Kwon H, et al. A prospective study of clozapine in treatment resistant patients: a preliminary report. Psychopharmacology (Berl). 1989;99(Suppl 68):S68–72.

    Article  Google Scholar 

  12. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545–73.

    Article  PubMed  CAS  Google Scholar 

  13. Tandon R, Belmaker Rh, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1–3):20–38.

    Article  PubMed  Google Scholar 

  14. Souza JS, Kayo M, Tassell I, et al. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013;18(2):82–9.

    Article  PubMed  Google Scholar 

  15. Attard A, Taylor DM. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us? CNS Drugs. 2012;26(6):491–508.

    Article  PubMed  CAS  Google Scholar 

  16. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25–35.

    Article  PubMed  CAS  Google Scholar 

  17. Taylor D, Shapland L, Laverick G, et al. Clozapine: a survey of patient perceptions. Psychiatr Bull. 2000;24:450–2.

    Article  Google Scholar 

Download references

Acknowledgement

The manuscript was reviewed by C.P. Alderman, Repatriation General Hospital, Adelaide (SA), Australia.

Disclosure

The preparation of this article was not supported by any external funding. During the review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, North Shore, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyseng-Williamson, K.A. Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. Drugs Ther Perspect 29, 161–165 (2013). https://doi.org/10.1007/s40267-013-0038-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-013-0038-8

Keywords

Search

Navigation